Company Filing History:
Years Active: 2012-2014
Title: Hugh Morgan: Innovator in Epigenetic Modification
Introduction
Hugh Morgan is a prominent inventor based in Cambridge, GB. He has made significant contributions to the field of molecular biology, particularly in the area of epigenetic modification. With a total of 2 patents, his work focuses on innovative methods for manipulating nucleic acid sequences.
Latest Patents
Hugh Morgan's latest patents include groundbreaking technologies. The first patent, titled "Molecules and methods for demethylation of methylated nucleic acid sequences," describes a method for demethylating a methylated DNA sequence in a eukaryotic cell. This method utilizes a molecule that includes a first domain exhibiting cytidine deaminase activity and a second domain that confers either specific or non-specific DNA binding activity. These molecules are particularly useful in somatic cell nuclear transfer and cancer therapy. The second patent, "Compositions and method for epigenetic modification of nucleic acid sequences in vivo," shares similar methodologies and applications, emphasizing the potential of these innovations in therapeutic contexts.
Career Highlights
Hugh Morgan is associated with Cellcentric Limited, where he continues to advance research in epigenetics. His work has positioned him as a key figure in the development of novel therapeutic strategies.
Collaborations
Hugh Morgan has collaborated with notable scientists, including Wolf Reik and Chun-Fung Chan. These partnerships have further enriched his research and contributed to the advancement of the field.
Conclusion
Hugh Morgan's innovative work in epigenetic modification showcases his commitment to advancing molecular biology. His patents reflect significant advancements that hold promise for future therapeutic applications.